Similar articles

• Methodological issues of non-inferiority trials in HIV-infected patients: a need for consensus?

  Richert L, Bouteloup V, Thiébaut R, Chêne G. Richert L, et al. AIDS. 2008 May 11;22(8):996-7. doi: 10.1097/QAD.0b013e3282ff6490. AIDS. 2008. PMID: 18453863 No abstract available.
• Should we now adopt the HIV-RNA < 50 copy endpoint for clinical trials of antiretroviral-experienced as well as naive patients?

  Hill A, Miralles D, Vangeneugden T, Lefebvre E. Hill A, et al. AIDS. 2007 Jul 31;21(12):1651-3. doi: 10.1097/QAD.0b013e3282703593. AIDS. 2007. PMID: 17630565
• Response adaptive designs with a variance-penalized criterion.

  Yi Y, Wang X. Yi Y, et al. Biom J. 2009 Oct;51(5):763-73. doi: 10.1002/bimj.200800233. Biom J. 2009. PMID: 19757432
• Key clinical trials of non-nucleoside reverse transcriptase inhibitors in the treatment of chronic HIV-1 infection in adults.

  Williams I. Williams I. J HIV Ther. 2008 Mar;13(1):19-23. J HIV Ther. 2008. PMID: 18953269 Review. No abstract available.
• Designing and interpreting HIV noninferiority trials in naive and experienced patients.

  Hill A, Sabin C. Hill A, et al. AIDS. 2008 May 11;22(8):913-21. doi: 10.1097/QAD.0b013e3282f5556d. AIDS. 2008. PMID: 18453850 Review. No abstract available.